Single Arm Clinical Trial of Small Molecule Natural Flavonoid Compounds for Intervention in Neurodegenerative Diseases

SMARTO ONE-202305-2

1. Explore the effects of natural plant flavonoids on the positive intervention mechanism of neurotransmitter transmission physiological indicators changes (EEG) in the brain of the study subjects; 2. Investigate the effects of natural plant flavonoids in positively intervening clinical symptoms of the study subjects.

2023-08-15

2024-06-15

2024-12-31

Not yet recruiting

30

Inclusion Criteria: 1. Age: 25-70 years 2. Patients complaining of sleep disorders, mood disorders (unstable mood, irritability, depression and anxiety) and cognitive decline (people with memory, decreased reaction time, BPSD symptoms) within one month 3. Montreal Cognitive Assessment Scale (MOCA) score ≤26; if MOCA score is not satisfied, then Pittsburgh Sleep Quality Index (PSQI) score \>10 and Hamilton Anxiety Scale (HAMA) score \>14 or Hamilton Depression Scale (HAMD) score ≥8 are required 4. Patients who can understand and communicate in language, and complete aphasia patients are not included; 5. Patients who agree to participate in this clinical observation and sign the informed consent form. Exclusion Criteria: 1. Patients with severe organ diseases such as heart, kidney, and liver failure, chronic lung diseases such as COPD, and severe diabetes; 2. Patients with severe uncontrolled hypertension; 3. Patients who have taken antipsychotic drugs within the past two weeks; 4. Patients with the core features of Lewy body dementia or significant behavioral variant frontotemporal dementia; 5. Patients with various malignant tumors; 6. Patients with progressive stroke, transient ischemic attack, cerebral hemorrhage after cerebral infarction, and cerebral arteritis; 7. Patients with brain tumors, brain trauma, cerebral parasitic diseases, and other conditions; 8. Pregnant or lactating women; 9. Patients allergic to the known ingredients used in this trial; 10. Patients with active ulcers or bleeding tendencies; 11. Patients with neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis, and Pick's disease; 12. Other patients who are deemed unsuitable to participate in this trial by the investigators.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}

2023-08-14